CEO‑CFO Snehal Patel Keeps Buying Greenwich Lifesciences Shares Amid Volatile High‑Growth Pitch
CEO‑CFO Snehal Patel’s latest 1,800‑share purchase at $29.83 shows disciplined insider confidence in Greenwich Lifesciences’ oncology pipeline, hinting that the high‑growth stock may still be a value play for investors despite volatile valuation mul…
3 minutes to read